Supplementary Table S1. Antiseptics and antifungals identified as hits in the primary screen

Drug Type	Drug Name	% Inhibition
Antiseptic	Thimerosal	>90%
Antiseptic	Clioquinol	>90%
Antiseptic	Thonzonium bromide	>90%
Antiseptic	Hexachlorophene	>90%
Antiseptic	Chlorhexidine	>90%
Antiseptic	Chloroxine	>90%
Antiseptic	Dequalinium dichloride	>90%
Antiseptic	Methyl benzethonium chloride	>90%
Antiseptic	Benzethonium chloride	>90%
Antiseptic	Alexidine dihydrochloride	>90%
Antiseptic	Merbromin	>90%
Antiseptic	Cycloheximide	>90%
Antifungal	Tioconazole	>90%
Antifungal	Ketoconazole	>90%
Antifungal	Ciclopirox ethanolamine	>90%
Antifungal	Terconazole	>90%
Antifungal	Voriconazole	>90%
Antifungal	Flucytosine	>90%

Ebselen $C_{13}H_9NOSe$



2-Phenyl-1,2-benzisoselenazol-3-(2H)-one

Supplementary Figure S1. Chemical Structure of Ebselen

Supplementary Table S2. Calculated IC_{50} values of ebselen for inhibition of planktonic growth and inhibition of biofilm formation against 10 *C. auris* strains. Values are in μg/ml. Parentheses indicate 95% confidence intervals (CI).

***Candida auris* strain**	**Planktonic IC_{50}**	**Biofilm IC_{50}**
0381	0.2514 (0.2446-0.2582)	6.067 (5.55-6.625)
0382	1.47 (1.266-1.697)	8.980 (undetermined)
0383	0.3898 (0.3355-0.4529)	9.781 (8.858-10.91)
0384	0.2412 (0.2011-0.2877)	7.432 (6.257-8.623)
0385	0.683 (0.5617-0.825)	9.164 (undetermined)
0386	0.6048 (0.5139-0.7071)	9.425 (undetermined)
0387	1.014 (0.8065-1.272)	9.006 (≤9.671)
0388	0.2345 (0.2018-0.2702)	8.821 (undetermined)
0389	1.211 (0.7223-1.459)	5.864 (undetermined)
0390	0.3777 (0.3391-0.4206)	8.050 (undetermined)

x



Supplementary Figure S2. Effect of ebselen on biofilm formation of 10 *C. auris* strains as revealed by crystal violet staining. A. Microscopic observations of the biofilms formed by the different strains. B. Dose-dependent inhibitory effect of ebselen on biofilm formation. Experiments were performed in two independent plates using duplicate wells in each plate. Bars indicate standard errors.



Supplementary Figure S3. Inhibitory activity of ebselen against different *Candida* spp. under planktonic growth conditions. Graphs depict inhibition by ebselen of planktonic growth for *C. albicans* and 6 other *Candida* species. Experiments were performed in two independent plates with two duplicate wells per plate. Bars indicate standard errors.



Supplementary Figure S4. Inhibitory activity of ebselen against different *Candida* spp. under biofilm growing conditions. Graphs depict ebselen inhibition of biofilm formation by *C. albicans* and 6 other *Candida* species. Experiments were performed in two independent plates with two duplicate wells per plate. Bars indicate standard errors.

Supplementary Table S3. Results of combination testing of ebselen with clinically-used antifungals against *C. auris* 0390.

	Inhibition of planktonic growth	**Inhibition of biofilm formation**
Ebselen-Fluconazole	Indifference (2.02)	Indifference (1.02)
Ebselen-Caspofungin	Indifference (2.50)	Indifference (1.02)
Ebselen- Amphotericin B	Indifference (2.25)	Indifference (1.01)

Note: Parentheses indicate the calculated FIC index value for each combination.

Supplementary Table S4. Results of combination testing of ebselen with clinically-used antifungals against *C. albicans* SC5314.

	Inhibition of planktonic growth	**Inhibition of biofilm formation**
Ebselen – Fluconazole	Synergy (0.27)	Indifference (0.62)
Ebselen – Caspofungin	Indifference (0.53)	Indifference (1.00)
Ebselen – Amphotericin B	Indifference (1.03)	Indifference (1.00)

Note: Parentheses indicate the calculated FIC index value for each combination.